One of the leading entities that issues physician guidelines for cancer medicines frequently recommends off-label uses beyond those endorsed by regulators, and relies on “weak evidence” to make its influential decisions, according to a new analysis published in BMJ.

Of 47 cancer drugs approved by the Food and Drug Administration between 2011 and 2015, the National Comprehensive Cancer Network recommended 113 uses for the medicines, while the agency endorsed the treatments for 69 uses. Of the 44 additional NCCN recommendations, 14, or 32 percent, permitted use for treating a cancer other than what was specified by the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy